130 related articles for article (PubMed ID: 27520724)
41. Heparin modification enhances the delivery and tumor targeting of paclitaxel-loaded N-octyl-N-trimethyl chitosan micelles.
Zhang F; Fei J; Sun M; Ping Q
Int J Pharm; 2016 Sep; 511(1):390-402. PubMed ID: 27426109
[TBL] [Abstract][Full Text] [Related]
42. Chemoradiation therapy using cyclopamine-loaded liquid-lipid nanoparticles and lutetium-177-labeled core-crosslinked polymeric micelles.
You J; Zhao J; Wen X; Wu C; Huang Q; Guan F; Wu R; Liang D; Li C
J Control Release; 2015 Mar; 202():40-8. PubMed ID: 25637565
[TBL] [Abstract][Full Text] [Related]
43. Improved anti-tumor activity and safety profile of a paclitaxel-loaded glycyrrhetinic acid-graft-hyaluronic acid conjugate as a synergistically targeted drug delivery system.
Zhang L; Zhou JP; Yao J
Chin J Nat Med; 2015 Dec; 13(12):915-24. PubMed ID: 26721710
[TBL] [Abstract][Full Text] [Related]
44. Low-density lipoprotein-coupled micelles with reduction and pH dual sensitivity for intelligent co-delivery of paclitaxel and siRNA to breast tumor.
Zhu WJ; Yang SD; Qu CX; Zhu QL; Chen WL; Li F; Yuan ZQ; Liu Y; You BG; Zhang XN
Int J Nanomedicine; 2017; 12():3375-3393. PubMed ID: 28490877
[TBL] [Abstract][Full Text] [Related]
45. Efficient Codelivery of Paclitaxel and Curcumin by Novel Bottlebrush Copolymer-based Micelles.
Yao Q; Gutierrez DC; Hoang NH; Kim D; Wang R; Hobbs C; Zhu L
Mol Pharm; 2017 Jul; 14(7):2378-2389. PubMed ID: 28605595
[TBL] [Abstract][Full Text] [Related]
46. Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells.
Zhou Y; Yang J; Kopeček J
Biomaterials; 2012 Feb; 33(6):1863-72. PubMed ID: 22138033
[TBL] [Abstract][Full Text] [Related]
47. Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance.
Wang L; Jia E
Drug Deliv; 2016 Jun; 23(5):1810-7. PubMed ID: 26530693
[TBL] [Abstract][Full Text] [Related]
48. Systematic evaluation of multifunctional paclitaxel-loaded polymeric mixed micelles as a potential anticancer remedy to overcome multidrug resistance.
Zhang J; Zhao X; Chen Q; Yin X; Xin X; Li K; Qiao M; Hu H; Chen D; Zhao X
Acta Biomater; 2017 Mar; 50():381-395. PubMed ID: 27956367
[TBL] [Abstract][Full Text] [Related]
49. Selective targeting by preS1 domain of hepatitis B surface antigen conjugated with phosphorylcholine-based amphiphilic block copolymer micelles as a biocompatible, drug delivery carrier for treatment of human hepatocellular carcinoma with paclitaxel.
Miyata R; Ueda M; Jinno H; Konno T; Ishihara K; Ando N; Kitagawa Y
Int J Cancer; 2009 May; 124(10):2460-7. PubMed ID: 19173297
[TBL] [Abstract][Full Text] [Related]
50. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo.
Zhong Y; Goltsche K; Cheng L; Xie F; Meng F; Deng C; Zhong Z; Haag R
Biomaterials; 2016 Apr; 84():250-261. PubMed ID: 26851390
[TBL] [Abstract][Full Text] [Related]
51. Paclitaxel-Loaded Mixed Micelles Enhance Ovarian Cancer Therapy through Extracellular pH-Triggered PEG Detachment and Endosomal Escape.
Zhao H; Li Q; Hong Z
Mol Pharm; 2016 Jul; 13(7):2411-22. PubMed ID: 27266442
[TBL] [Abstract][Full Text] [Related]
52. Targeted inhibition of hedgehog signaling by cyclopamine prodrugs for advanced prostate cancer.
Kumar SK; Roy I; Anchoori RK; Fazli S; Maitra A; Beachy PA; Khan SR
Bioorg Med Chem; 2008 Mar; 16(6):2764-8. PubMed ID: 18249125
[TBL] [Abstract][Full Text] [Related]
53. Cyclopamine disrupts tumor extracellular matrix and improves the distribution and efficacy of nanotherapeutics in pancreatic cancer.
Zhang B; Jiang T; Shen S; She X; Tuo Y; Hu Y; Pang Z; Jiang X
Biomaterials; 2016 Oct; 103():12-21. PubMed ID: 27376555
[TBL] [Abstract][Full Text] [Related]
54. Development and evaluation of a novel TPGS-mediated paclitaxel-loaded PLGA-mPEG nanoparticle for the treatment of ovarian cancer.
Lv W; Cheng L; Li B
Chem Pharm Bull (Tokyo); 2015; 63(2):68-74. PubMed ID: 25451039
[TBL] [Abstract][Full Text] [Related]
55. In vivo evaluation of novel chitosan graft polymeric micelles for delivery of paclitaxel.
Liu J; Li H; Chen D; Jin X; Zhao X; Zhang C; Ping Q
Drug Deliv; 2011 Apr; 18(3):181-9. PubMed ID: 20942638
[TBL] [Abstract][Full Text] [Related]
56. Aminoglucose-functionalized, redox-responsive polymer nanomicelles for overcoming chemoresistance in lung cancer cells.
Zhou Y; Wen H; Gu L; Fu J; Guo J; Du L; Zhou X; Yu X; Huang Y; Wang H
J Nanobiotechnology; 2017 Nov; 15(1):87. PubMed ID: 29179722
[TBL] [Abstract][Full Text] [Related]
57. Thermosensitive poly(organophosphazene)-paclitaxel conjugate gels for antitumor applications.
Chun C; Lee SM; Kim SY; Yang HK; Song SC
Biomaterials; 2009 Apr; 30(12):2349-60. PubMed ID: 19178941
[TBL] [Abstract][Full Text] [Related]
58. Paclitaxel-loaded N-octyl-O-sulfate chitosan micelles for superior cancer therapeutic efficacy and overcoming drug resistance.
Jin X; Mo R; Ding Y; Zheng W; Zhang C
Mol Pharm; 2014 Jan; 11(1):145-57. PubMed ID: 24261922
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel.
Zhang C; Qu G; Sun Y; Wu X; Yao Z; Guo Q; Ding Q; Yuan S; Shen Z; Ping Q; Zhou H
Biomaterials; 2008 Mar; 29(9):1233-41. PubMed ID: 18093646
[TBL] [Abstract][Full Text] [Related]
60. Integrin-targeted nano-sized polymeric systems for paclitaxel conjugation: a comparative study.
Eldar-Boock A; Blau R; Ryppa C; Baabur-Cohen H; Many A; Vicent MJ; Kratz F; Sanchis J; Satchi-Fainaro R
J Drug Target; 2017; 25(9-10):829-844. PubMed ID: 28737432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
